Oscar Ramirez
Research Subjects
Oscar Ramirez has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Paula Aristizabal
Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of California San Diego/Rady Children’s Health, San Diego, USA
5 shared publications - Santiago Bolivar
Pontificia Universidad Javeriana
5 shared publications - Luis Eduardo Bravo
Facultad de Salud, Universidad del Valle. Cali, Colombia
3 shared publications Paula Aristizabal
15 Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of California, San Diego, San Diego, CA, United States
3 shared publicationsVivian Piedrahita
Research Unit Fundación POHEMA Cali Colombia
3 shared publicationsViviana Lotero
Fundación POHEMA, Cali, Colombia
3 shared publications
Latest Publications
- 29 April 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (7) , e70365
Co‐Development and Usability Testing of S‐IMCICA: A User‐Centered Web‐Based E‐Learning Curriculum in Early Childhood Cancer Detection for Primary Care Providers in Colombia
Early detection is critical to improving childhood cancer survival. In 2013, the Pan American Health Organization published the Integrated Management of Childhood Illnesses‐Cancer manual. We found that only 13% ( n = 21/161) of primary care providers (PCPs) in southwestern Colombia were familiar with this manual. In response, we iteratively co‐developed an e‐learning curriculum (S‐IMCICA) with PCPs, oncologists, and health educators, and applied usability testing for refinement (five iterations; usability testing in 919 PCPs). Usability testing showed mean increases in knowledge of 21%–24% (60%–65% vs. 81%–89%; p < 0.01) and excellent usability ratings. Our user‐centered e‐learning curriculum contributes to building capacity among PCPs for early childhood cancer detection in low‐ and middle‐income countries.
- 29 April 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (7) , e70365
Co‐Development and Usability Testing of S‐IMCICA: A User‐Centered Web‐Based E‐Learning Curriculum in Early Childhood Cancer Detection for Primary Care Providers in Colombia
Early detection is critical to improving childhood cancer survival. In 2013, the Pan American Health Organization published the Integrated Management of Childhood Illnesses‐Cancer manual. We found that only 13% ( n = 21/161) of primary care providers (PCPs) in southwestern Colombia were familiar with this manual. In response, we iteratively co‐developed an e‐learning curriculum (S‐IMCICA) with PCPs, oncologists, and health educators, and applied usability testing for refinement (five iterations; usability testing in 919 PCPs). Usability testing showed mean increases in knowledge of 21%–24% (60%–65% vs. 81%–89%; p < 0.01) and excellent usability ratings. Our user‐centered e‐learning curriculum contributes to building capacity among PCPs for early childhood cancer detection in low‐ and middle‐income countries.
- Open Access
- 10 June 2025
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 12 (1-Supl)
Suplemento Especial - Resúmenes de Investigación: XXXVI Congreso de Sociedad Latinoamericana de Oncología Pediátrica (SLAOP) y XXIII Congreso de la Asociación Colombiana de Hematología y Oncología Pediátrica – Cali, junio del 2025
- 10 June 2025
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 12 (1-Supl)
Open AccessSuplemento Especial - Resúmenes de Investigación: XXXVI Congreso de Sociedad Latinoamericana de Oncología Pediátrica (SLAOP) y XXIII Congreso de la Asociación Colombiana de Hematología y Oncología Pediátrica – Cali, junio del 2025
- Open Access
- 10 June 2025
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 12 (1-Supl)
Colaboración como estrategia para mejorar la atención del cáncer infantil en países de ingresos bajos y medios: El modelo de VIGICANCER en Colombia
Introducción: Colaborar en oncología pediátrica permite abordar y entender a fondo problemáticas complejas en salud como las disparidades en la supervivencia de cáncer infantil en países de ingresos bajos y medios. Describimos la implementación de VIGICANCER, el sistema de vigilancia de desenlaces clínicos en cáncer infantil de Colombia, un ejemplo de colaboración enfocado en mejorar la supervivencia de niños y adolescentes con cáncer en nuestro país. Métodos: diversas iniciativas de colaboración se han establecido en países de ingresos bajos y medios, que demuestran avances en nuestro entendimiento de los mecanismos que contribuyen a inequidades en nuestros países. Se destacan proyectos y programas encauzados a mejorar los desenlaces de los niños con cáncer. Estas iniciativas incluyen programas de “hermanamiento”, alianzas nacionales, regionales, internacionales y conformación de grupos cooperativos de investigación. Resultados: entre estas iniciativas se destaca VIGICANCER, establecido en alianza entre el Registro Poblacional de Cáncer de Cali (RPCC), la Fundación de Pediatras Oncólogos y Hematólogos (POHEMA) y la Asociación Colombiana de Oncología y Hematología Pediátrica (ACHOP). Este se ha posicionado como referente de colaboración e investigación en América Latina, contribuyendo con importantes lecciones para su réplica en otros países de ingresos bajos y medios. Conclusiones: VIGICANCER ha establecido el precedente para futuras rutas de trabajo colaborativas enfocadas en incluir la epidemiología del cáncer y los mecanismos causantes de disparidades en los desenlaces clínicos en cáncer infantil en Colombia, con el objetivo final de mejorar de manera equitativa la supervivencia en niños y adolescentes con cáncer en nuestro país y en América Latina.
- 10 June 2025
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 12 (1-Supl)
Open AccessColaboración como estrategia para mejorar la atención del cáncer infantil en países de ingresos bajos y medios: El modelo de VIGICANCER en Colombia
Introducción: Colaborar en oncología pediátrica permite abordar y entender a fondo problemáticas complejas en salud como las disparidades en la supervivencia de cáncer infantil en países de ingresos bajos y medios. Describimos la implementación de VIGICANCER, el sistema de vigilancia de desenlaces clínicos en cáncer infantil de Colombia, un ejemplo de colaboración enfocado en mejorar la supervivencia de niños y adolescentes con cáncer en nuestro país. Métodos: diversas iniciativas de colaboración se han establecido en países de ingresos bajos y medios, que demuestran avances en nuestro entendimiento de los mecanismos que contribuyen a inequidades en nuestros países. Se destacan proyectos y programas encauzados a mejorar los desenlaces de los niños con cáncer. Estas iniciativas incluyen programas de “hermanamiento”, alianzas nacionales, regionales, internacionales y conformación de grupos cooperativos de investigación. Resultados: entre estas iniciativas se destaca VIGICANCER, establecido en alianza entre el Registro Poblacional de Cáncer de Cali (RPCC), la Fundación de Pediatras Oncólogos y Hematólogos (POHEMA) y la Asociación Colombiana de Oncología y Hematología Pediátrica (ACHOP). Este se ha posicionado como referente de colaboración e investigación en América Latina, contribuyendo con importantes lecciones para su réplica en otros países de ingresos bajos y medios. Conclusiones: VIGICANCER ha establecido el precedente para futuras rutas de trabajo colaborativas enfocadas en incluir la epidemiología del cáncer y los mecanismos causantes de disparidades en los desenlaces clínicos en cáncer infantil en Colombia, con el objetivo final de mejorar de manera equitativa la supervivencia en niños y adolescentes con cáncer en nuestro país y en América Latina.
- Open Access
- 9 January 2025
- Published by Wiley
VIGICANCER: Understanding “real-world” clinical outcomes in children and adolescents with cancer in Colombia to inform cancer control policy
Given scarce data on childhood cancer outcomes in Colombia and discrepancies among hospital-based, population-based, and government registries, we implemented VIGICANCER, a childhood cancer clinical outcomes surveillance system to collect, analyze, and disseminate valid, reliable, and timely data. VIGICANCER has expanded to ten Colombian cities, achieving inclusion of 55-60% of children nationwide. VIGICANCER yields key, exhaustive, and actionable population-based information, guides multilevel interventions, and informs public policy while providing timely feedback to participating institutions. VIGICANCER’s systematic results have positioned our childhood cancer surveillance system as a successful model in Latin America, reproducible in other low–and middle-income countries with similar contexts.
- 9 January 2025
- Published by Wiley
Open AccessVIGICANCER: Understanding “real-world” clinical outcomes in children and adolescents with cancer in Colombia to inform cancer control policy
Given scarce data on childhood cancer outcomes in Colombia and discrepancies among hospital-based, population-based, and government registries, we implemented VIGICANCER, a childhood cancer clinical outcomes surveillance system to collect, analyze, and disseminate valid, reliable, and timely data. VIGICANCER has expanded to ten Colombian cities, achieving inclusion of 55-60% of children nationwide. VIGICANCER yields key, exhaustive, and actionable population-based information, guides multilevel interventions, and informs public policy while providing timely feedback to participating institutions. VIGICANCER’s systematic results have positioned our childhood cancer surveillance system as a successful model in Latin America, reproducible in other low–and middle-income countries with similar contexts.
- Open Access
- 23 December 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (24) , e70483
Increased Early‐Mortality in Children With Solid Tumors During the COVID‐19 Pandemic in a Middle‐Income Country
Background: Measures to control COVID‐19 transmission disrupted childhood cancer care. Data on the effects of the COVID‐19 pandemic on childhood cancer mortality are lacking. This study describes the impact of the pandemic on childhood cancer early‐mortality (≤ 24 months).Methods: A multicenter prospective cohort was conducted in 10 Colombian cities. Children with newly diagnosed cancer registered in the Childhood Cancer Clinical Outcomes Surveillance System (VIGICANCER) were included. Our primary outcome was cumulative mortality at 3, 6, 12, and 24 months. The exposed cohort (EC = March 25, 2020–December 31, 2021) was compared with a historic cohort (HC = January 1, 2017–March 24, 2020). Covariates included sociodemographics, place of residence, health insurance type, and tumor classification.Results: The cohort included 4124 children, comprised of 1627 children in the EC and 2497 children in the HC. Hematolymphoid, central nervous system, and extracranial solid tumors represented 57%, 15%, and 28% of patients, respectively. Participants' median age was 6.7 years (IQR, 3.2–11.3), 54% were male, 7% were Afro‐descendant, and 47% had public insurance. In the EC, the 6‐month and 24‐month mortality adjusted hazard ratio (aHR) in children with solid tumors was 1.7 (95% CI, 1.1–2.7) and 1.3 (95% CI, 1.0–1.7), respectively, and in children with bone tumors 4.0 (95% CI, 1.2–13.0) and 2.1 (95% CI, 1.2–3.6), respectively. These associations persisted after accounting for metastatic disease. Six‐month mortality aHRs for retinoblastoma, bone tumors, and soft tissue sarcomas due to progressive disease were 4.3 (95% CI, 1.3–14.5), 4.0 (95% CI, 1.4–11.3), and 5.4 (95% CI, 2.2–13.5), respectively. In the EC, the adjusted odds ratio (aOR) for metastatic solid tumors vs. nonmetastatic was 1.4 (95% CI, 1.0–1.8) and in children with retinoblastoma and public insurance the 24‐month mortality aHR was 4.9 (95% CI, 1.1–21.7).Conclusions: We observed increased early‐mortality for solid tumors, particularly bone tumors and retinoblastoma, likely attributed to more advanced‐stage presentation and loss of treatment effectiveness due to healthcare disruptions. Early‐mortality was higher in patients with public insurance, a vulnerable population that warrants attention.
- 23 December 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (24) , e70483
Open AccessIncreased Early‐Mortality in Children With Solid Tumors During the COVID‐19 Pandemic in a Middle‐Income Country
Background: Measures to control COVID‐19 transmission disrupted childhood cancer care. Data on the effects of the COVID‐19 pandemic on childhood cancer mortality are lacking. This study describes the impact of the pandemic on childhood cancer early‐mortality (≤ 24 months).Methods: A multicenter prospective cohort was conducted in 10 Colombian cities. Children with newly diagnosed cancer registered in the Childhood Cancer Clinical Outcomes Surveillance System (VIGICANCER) were included. Our primary outcome was cumulative mortality at 3, 6, 12, and 24 months. The exposed cohort (EC = March 25, 2020–December 31, 2021) was compared with a historic cohort (HC = January 1, 2017–March 24, 2020). Covariates included sociodemographics, place of residence, health insurance type, and tumor classification.Results: The cohort included 4124 children, comprised of 1627 children in the EC and 2497 children in the HC. Hematolymphoid, central nervous system, and extracranial solid tumors represented 57%, 15%, and 28% of patients, respectively. Participants' median age was 6.7 years (IQR, 3.2–11.3), 54% were male, 7% were Afro‐descendant, and 47% had public insurance. In the EC, the 6‐month and 24‐month mortality adjusted hazard ratio (aHR) in children with solid tumors was 1.7 (95% CI, 1.1–2.7) and 1.3 (95% CI, 1.0–1.7), respectively, and in children with bone tumors 4.0 (95% CI, 1.2–13.0) and 2.1 (95% CI, 1.2–3.6), respectively. These associations persisted after accounting for metastatic disease. Six‐month mortality aHRs for retinoblastoma, bone tumors, and soft tissue sarcomas due to progressive disease were 4.3 (95% CI, 1.3–14.5), 4.0 (95% CI, 1.4–11.3), and 5.4 (95% CI, 2.2–13.5), respectively. In the EC, the adjusted odds ratio (aOR) for metastatic solid tumors vs. nonmetastatic was 1.4 (95% CI, 1.0–1.8) and in children with retinoblastoma and public insurance the 24‐month mortality aHR was 4.9 (95% CI, 1.1–21.7).Conclusions: We observed increased early‐mortality for solid tumors, particularly bone tumors and retinoblastoma, likely attributed to more advanced‐stage presentation and loss of treatment effectiveness due to healthcare disruptions. Early‐mortality was higher in patients with public insurance, a vulnerable population that warrants attention.
- Open Access
- 27 February 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1326788
Primary central nervous system tumors survival in children in ten Colombian cities: a VIGICANCER report
Purpose: Primary central nervous system (CNS) tumors are the second most common cancer in children and adolescents, leading to premature death and disability. Population-based survival estimates aid decision-making in cancer control, however data on survival for primary CNS tumors in Latin America is lacking. We describe survival rates for children with primary CNS tumors treated in ten Colombian cities.Methods: We analyzed data from children and adolescents newly diagnosed with cancer between 2012 and 2021, participating in the Childhood Cancer Clinical Outcomes Surveillance System (VIGICANCER) in ten cities in Colombia. VIGICANCER collects information on clinical outcomes from twenty-seven pediatric oncology units and conducts active follow-up every three months. VIGICANCER does not register craniopharyngiomas; we excluded intracranial germ cell tumors for this report. We used the Kaplan-Meier method to estimate the overall survival probability, stratified by sociodemographic variables, topography, WHO grading, receipt of radiation therapy, and type of surgical resection. We analyzed the prognostic capacity of variables using multivariate proportional Cox’s regression, stratified by city and year of diagnosis.Results: During the study period, VIGICANCER included 989 primary CNS tumors in 879 children and 110 adolescents. The cohort median age was 9 years; 53% of patients were males, and 8% were Afro-descendants. Most common tumors were supratentorial astrocytomas (47%), astrocytic tumors (35%), medulloblastomas (20%), ependymomas (11%), and mixed and unspecified gliomas (10%). Five-year overall survival of the entire cohort was 54% (95% CI, 51-58); for supratentorial gliomas, WHO grade I was 77%, II was 62%, III-IV was 27%, respectively, and for medulloblastoma was 61%. The adjusted hazard rate ratio for patients with WHO grade III and IV, for those with subtotal resection, for brainstem location, and for those not receiving radiation therapy was 7.4 (95% CI, 4.7–11.8), 6.4 (95% CI, 4.2–9.8), 2.8 (95% 2.1–3.8), 2.0 (95% CI, 1.3–2.8) and 2.3 (95% CI, 1.7–3.0), respectively.Conclusion: We found that half of Colombia’s children and adolescents with primary CNS tumors survive five years, compared to 70% to 80% in high-income countries. In addition to tumor biology and location, gross total resection was crucial for improved survival in this cohort. Systematic monitoring of survival and its determinants provides empirical data for guiding cancer control policies.
- 27 February 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1326788
Open AccessPrimary central nervous system tumors survival in children in ten Colombian cities: a VIGICANCER report
Purpose: Primary central nervous system (CNS) tumors are the second most common cancer in children and adolescents, leading to premature death and disability. Population-based survival estimates aid decision-making in cancer control, however data on survival for primary CNS tumors in Latin America is lacking. We describe survival rates for children with primary CNS tumors treated in ten Colombian cities.Methods: We analyzed data from children and adolescents newly diagnosed with cancer between 2012 and 2021, participating in the Childhood Cancer Clinical Outcomes Surveillance System (VIGICANCER) in ten cities in Colombia. VIGICANCER collects information on clinical outcomes from twenty-seven pediatric oncology units and conducts active follow-up every three months. VIGICANCER does not register craniopharyngiomas; we excluded intracranial germ cell tumors for this report. We used the Kaplan-Meier method to estimate the overall survival probability, stratified by sociodemographic variables, topography, WHO grading, receipt of radiation therapy, and type of surgical resection. We analyzed the prognostic capacity of variables using multivariate proportional Cox’s regression, stratified by city and year of diagnosis.Results: During the study period, VIGICANCER included 989 primary CNS tumors in 879 children and 110 adolescents. The cohort median age was 9 years; 53% of patients were males, and 8% were Afro-descendants. Most common tumors were supratentorial astrocytomas (47%), astrocytic tumors (35%), medulloblastomas (20%), ependymomas (11%), and mixed and unspecified gliomas (10%). Five-year overall survival of the entire cohort was 54% (95% CI, 51-58); for supratentorial gliomas, WHO grade I was 77%, II was 62%, III-IV was 27%, respectively, and for medulloblastoma was 61%. The adjusted hazard rate ratio for patients with WHO grade III and IV, for those with subtotal resection, for brainstem location, and for those not receiving radiation therapy was 7.4 (95% CI, 4.7–11.8), 6.4 (95% CI, 4.2–9.8), 2.8 (95% 2.1–3.8), 2.0 (95% CI, 1.3–2.8) and 2.3 (95% CI, 1.7–3.0), respectively.Conclusion: We found that half of Colombia’s children and adolescents with primary CNS tumors survive five years, compared to 70% to 80% in high-income countries. In addition to tumor biology and location, gross total resection was crucial for improved survival in this cohort. Systematic monitoring of survival and its determinants provides empirical data for guiding cancer control policies.
- Open Access
- 1 December 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 7 (7) , 901-916
C/Can City Engagement Process: An Implementation Framework for Strengthening Cancer Care in Cities in Low- and Middle-Income Countries
The effective implementation of locally adapted cancer care solutions in low- and middle-income countries continues to be a challenge in the face of fragmented and inadequately resourced health systems. Consequently, the translation of global cancer care targets to local action for patients has been severely constrained. City Cancer Challenge (C/Can) is leveraging the unique value of cities as enablers in a health systems response to cancer that prioritizes the needs of end users (patients, their caregivers and families, and health care providers). C/Can’s City Engagement Process is an implementation framework whereby local stakeholders lead a staged city-wide process over a 2- to 3-year period to assess, plan, and execute locally adapted cancer care solutions. Herein, the development and implementation of the City Engagement Process Framework (CEPF) is presented, specifying the activities, outputs, processes, and indicators across the process life cycle. Lessons learned on the application of the framework in the first so-called Key Learning cities are shared, focusing on the early outputs from Cali, Colombia, the first city to join C/Can in 2017. Creating lasting change requires the creation of a high-trust environment to engage the right stakeholders as well as adapting to local context, leveraging local expertise, and fostering a sustainability mindset from the outset. In the short term, these early learnings inform the refinement of the approach in new cities. Over time, the implementation of this framework is expected to validate the proof-of-concept and contribute to a global evidence base for effective complex interventions to improve cancer care in low- and middle-income countries.
- 1 December 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 7 (7) , 901-916
Open AccessC/Can City Engagement Process: An Implementation Framework for Strengthening Cancer Care in Cities in Low- and Middle-Income Countries
The effective implementation of locally adapted cancer care solutions in low- and middle-income countries continues to be a challenge in the face of fragmented and inadequately resourced health systems. Consequently, the translation of global cancer care targets to local action for patients has been severely constrained. City Cancer Challenge (C/Can) is leveraging the unique value of cities as enablers in a health systems response to cancer that prioritizes the needs of end users (patients, their caregivers and families, and health care providers). C/Can’s City Engagement Process is an implementation framework whereby local stakeholders lead a staged city-wide process over a 2- to 3-year period to assess, plan, and execute locally adapted cancer care solutions. Herein, the development and implementation of the City Engagement Process Framework (CEPF) is presented, specifying the activities, outputs, processes, and indicators across the process life cycle. Lessons learned on the application of the framework in the first so-called Key Learning cities are shared, focusing on the early outputs from Cali, Colombia, the first city to join C/Can in 2017. Creating lasting change requires the creation of a high-trust environment to engage the right stakeholders as well as adapting to local context, leveraging local expertise, and fostering a sustainability mindset from the outset. In the short term, these early learnings inform the refinement of the approach in new cities. Over time, the implementation of this framework is expected to validate the proof-of-concept and contribute to a global evidence base for effective complex interventions to improve cancer care in low- and middle-income countries.
- Open Access
- 8 September 2021
- Published by Elsevier in Jornal de Pediatria
- Vol. 98 (3) , 282-288
Renal volume of five-year-old preterm children are not different than full-term controls
- 8 September 2021
- Published by Elsevier in Jornal de Pediatria
- Vol. 98 (3) , 282-288
Open AccessRenal volume of five-year-old preterm children are not different than full-term controls
- Open Access
- 1 December 2018
- Published by Elsevier in Pediatric Hematology Oncology Journal
- Vol. 3 (4) , 79-87
Childhood cancer survival disparities in a universalized health system in Cali, Colombia
- 1 December 2018
- Published by Elsevier in Pediatric Hematology Oncology Journal
- Vol. 3 (4) , 79-87
Open AccessChildhood cancer survival disparities in a universalized health system in Cali, Colombia
- Open Access
- 1 December 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Global Oncology
- Vol. 4 (4) , 1-11
Implementing a Childhood Cancer Outcomes Surveillance System Within a Population-Based Cancer Registry
Purpose: Approximately 80% of cases of childhood cancer occur in low- and middle-income countries and are associated with high mortality rates. Assessing outcomes is essential for designing effective strategies to improve outcomes equally worldwide. We implemented a real-time surveillance system, VIGICANCER, embedded in a population-based cancer registry (PBCR) to assess childhood cancer outcomes. Methods: VIGICANCER was established in 2009 as an integral part of Cali’s PBCR to collect real-time data on outcomes of patients (age < 19 years) with a new diagnosis of cancer treated in pediatric oncology units in Cali, Colombia. Baseline and follow-up data (death, relapse, treatment abandonment, second neoplasms) were collected from medical records, hospital discharge logs, pathology reports, death certificates, and the National Public Health Insurance database. A quality assurance process was implemented for the system. Results: From 2009 to 2013, data from 1,242 patients were included in VIGICANCER: 32% of patients were younger than 5 years, 55% were male, and 15% were Afro-descendants. International Classification of Childhood Cancer group I diagnoses predominated in all age groups except children younger than 1 year old, in whom CNS tumors predominated. Five-year overall survival for all cancers was 51.7% (95% CI, 47.9% to 55.4%) for children (< 15 years), and 39.4% (95% CI, 29.8% to 50.5%) for adolescents (15 to 18.9 years). Five-year overall survival for acute lymphoblastic leukemia was 55.6% (95% CI, 48.5% to 62.2%). Conclusion: Our study demonstrates the feasibility of implementing a real-time childhood cancer outcomes surveillance system embedded in a PBCR that can guide interventions to improve clinical outcomes in low- and middle-income countries.
- 1 December 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Global Oncology
- Vol. 4 (4) , 1-11
Open AccessImplementing a Childhood Cancer Outcomes Surveillance System Within a Population-Based Cancer Registry
Purpose: Approximately 80% of cases of childhood cancer occur in low- and middle-income countries and are associated with high mortality rates. Assessing outcomes is essential for designing effective strategies to improve outcomes equally worldwide. We implemented a real-time surveillance system, VIGICANCER, embedded in a population-based cancer registry (PBCR) to assess childhood cancer outcomes. Methods: VIGICANCER was established in 2009 as an integral part of Cali’s PBCR to collect real-time data on outcomes of patients (age < 19 years) with a new diagnosis of cancer treated in pediatric oncology units in Cali, Colombia. Baseline and follow-up data (death, relapse, treatment abandonment, second neoplasms) were collected from medical records, hospital discharge logs, pathology reports, death certificates, and the National Public Health Insurance database. A quality assurance process was implemented for the system. Results: From 2009 to 2013, data from 1,242 patients were included in VIGICANCER: 32% of patients were younger than 5 years, 55% were male, and 15% were Afro-descendants. International Classification of Childhood Cancer group I diagnoses predominated in all age groups except children younger than 1 year old, in whom CNS tumors predominated. Five-year overall survival for all cancers was 51.7% (95% CI, 47.9% to 55.4%) for children (< 15 years), and 39.4% (95% CI, 29.8% to 50.5%) for adolescents (15 to 18.9 years). Five-year overall survival for acute lymphoblastic leukemia was 55.6% (95% CI, 48.5% to 62.2%). Conclusion: Our study demonstrates the feasibility of implementing a real-time childhood cancer outcomes surveillance system embedded in a PBCR that can guide interventions to improve clinical outcomes in low- and middle-income countries.